Research programme: serine/threonine protein kinase inhibitors - Onconova Therapeutics

Drug Profile

Research programme: serine/threonine protein kinase inhibitors - Onconova Therapeutics

Alternative Names: CDK4 inhibitors - Onconova; ON 108110; ON 108600; ON-123300

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Onconova Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai; Onconova Therapeutics
  • Class Pyrimidines; Thiazines
  • Mechanism of Action Casein kinase II inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; NUAK1 protein inhibitors; PIM3 protein inhibitors; Protein kinase inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Colorectal cancer
  • Research Breast cancer

Most Recent Events

  • 21 Mar 2017 Onconova has patent protection for ON 123300 worldwide
  • 20 Apr 2016 Preclinical trials in Colorectal cancer in USA (unspecified route)
  • 07 Apr 2016 Pharmacodynamics data from preclinical and in vitro studies in Colorectal cancer presented at the 107th Annual Meeting of the Americal Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top